Natalie Sacks
Independent DirectorDr. Natalie R. Sacks, M.D. is Director at Clasp Therapeutics Inc. since 2025. She serves as Partner at Novo Holdings Equity US, Inc. She is Director of Rondo Therapeutics, Inc. from June 2024. She is Director at Reunion Neuroscience Inc. since 2024. She is Director at Reunion Neuroscience Management, Inc. Dr. Sacks serves as Venture Partner at Novo Holdings A/S since joining in 2022. She served as Chief Medical Offer since October 3, 2018 until June 01, 2022. She was the Chief Medical Officer at Harpoon Therapeutics, Inc. from October 2018 to June 2022. Dr. Sacks is a Venture Partner at Novo Ventures. Dr. Sacks serves as an Independent Director of Caribou Biosciences, Inc. since May 2018. She has been a Director of STipe Therapeutics since April 2020. Dr. Sacks was Executive Officer at Aduro BioTech, Inc. since October 1, 2018. Dr. Sacks served as Chief Medical Officer of Aduro BioTech, Inc. since September 2016 until September 2018. Dr. Sacks has clinical background as well as her broad experience in all aspects of product development is from global clinical and regulatory strategy through reimbursement and expansion indications is instrumental in guiding internal and Partnered programs. Prior to joining Aduro, Dr. Sacks served as an Advisor on development strategy for multiple firms. She served as Vice President of Clinical Development at Onyx Pharmaceuticals from April 2011 to February 2014, where she served a key role in the development and approval of Kyprolis® and in business development strategy. She served as Vice President of Clinical Research for Exelixis, Inc. from September 2009 to March 2011 where she directed the development of a portfolio of small molecules, ranging from IND filing to late-stage development, including Cometriqa. She served positions of increasing responsibility at Cell Genesys, culminating as Vice President of Clinical Development from November 2002 to April 2009. She served in a variety of research and analytical roles at academic institutions and companies including Massachusetts General Hospital, Medical College of Pennsylvania and ICI-Stuart Pharmaceuticals. She had been an Independent Director of Zymeworks Inc. since August 02, 2017 until June 30, 2023. She serves as a Director of Caribou Biosciences since May 2018. From October 2004 to October 2016, Dr. Sacks was an Assistant Clinical Professor at the University of California, San Francisco from 2003 to 2017 and served as volunteer Attending Physician in Hematology-Oncology at San Francisco General Hospital for more than a decade. She received her M.D. from the University of Pennsylvania School Of Medicine, her M.S. in Biostatistics from Harvard University T.H. Chan School of Public Health and her B.A. in Mathematics from Bryn Mawr College.
Positions
- Company NameCaribou Biosciences, Inc.Stock CodeCRBUPositionIndependent DirectorColleagues
- RERachel E. HaurwitzCo-Founder, CEO, President & Director
- ALAndrew L. GuggenhimeIndependent Chairman
- SRSriram RyaliChief Financial Officer
- BGBarbara G. McClungChief Legal Officer & Corporate Secretary
- JAJennifer A. DoudnaCo-founder & Member of Scientific Advisory Board
- RFRyan FischesserInterim Principal Accounting Officer & Controller
- SNScott N. BraunsteinIndependent Director
